Active Ingredient History

NOW
  • Now
Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine.   NCATS

  • SMILES: ClCCNC(=O)N(CCCl)N=O
  • InChIKey: DLGOEMSEDOSKAD-UHFFFAOYSA-N
  • Mol. Mass: 214.05
  • ALogP: 1.16
  • ChEMBL Molecule:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2996.6125 - $3869.8125

Australia

$11571.4455
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bcnu | becenun | bicnu | bicnu (tn) | bis-chloroethylnitrosourea | bischloroethyl nitrosourea | carmubris | carmustin | carmustina | carmustine | carmustinum | nitrumon | n,n'-bis(2-chloroethyl)-n-nitrosourea

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue